FCMV
ALLO icon

Foresite Capital Management VI’s Allogene Therapeutics ALLO Stock Holding History

Foresite Capital Management VI’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-2,875,357
Closed -$3.25M – 13
2025
Q2 		$3.25M Sell
2,875,357
-572,918
-17% -$761K 1.83% 15
2025
Q1 		$5.03M Hold
3,448,275
– – 2.76% 9
2024
Q4 		$7.34M Buy
+3,448,275
New +$8.5M 3.27% 11

Other funds holding ALLO

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Foresite Capital Management VI's ALLO Position: Q3 2025 in Review

Foresite Capital Management VI sold out of Allogene Therapeutics (ALLO) in Q3 2025, closing a stake of 2,875,357 shares — an estimated $3.25M sold.

Foresite Capital Management VI first reported a position in ALLO in Q4 2024 and held it in 3 quarters. The position peaked at $7.34M in Q4 2024. 170 funds tracked by Wall St. Rank hold ALLO as of Q3 2025.

  • Foresite Capital Management VI reported no remaining Allogene Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Foresite Capital Management VI sold 2,875,357 Allogene Therapeutics shares in Q3 2025, an estimated $3.25M.
  • Foresite Capital Management VI first reported a position in Allogene Therapeutics in Q4 2024 and held it in 3 quarters.
  • Foresite Capital Management VI's Allogene Therapeutics position peaked at $7.34M in Q4 2024.
  • 170 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q3 2025.

Based on Foresite Capital Management VI's 13F filing for Q3 2025, filed 14 Nov 2025.